Login
$OPK
$1.62 +$0.00 (0.07%) After hours

$OPK SEC Filings

Filed On Filing
06 Nov 2026 SCHEDULE 13D/A
05 Nov 2026 Form 4: Paganelli John A, Director

Sold 13,601 shares ($24.6K)

04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

MIAMI, November 4, 2026 – OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026.

15 Oct 2026 8-K: Entry into a Material Definitive Agreement

CERTAIN INFORMATION CONTAINED IN THIS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PR...

02 Oct 2026 8-K: Other Events

On October 1, 2026, OPKO Health, Inc. (the “Company”) determined that its 3.75% Convertible Senior Notes due 2029 (the “Notes”), of which approximately $121 million is outstanding, are convertible by holders of such Notes through Decembe...

28 Aug 2026 10-Q/A
28 Aug 2026 10-Q/A
14 Aug 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On August 13, 2026, OPKO Health, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the initial Note Purchase Agreement dated July 17, 2024 (the “Original Agreement”; and as amended by the Amendment, the “Amended Agreeme...

07 Aug 2026 SCHEDULE 13D
28 Jul 2026 Form 4: Logal Adam, Sr. Vice President, CFO

Gave up 53,266 shares to cover exercise price or tax ($65K)

28 Jul 2026 Form 4: Rubin Steven D, Director

Gave up 53,266 shares to cover exercise price or tax ($65K)

27 Jul 2026 10-Q
27 Jul 2026 8-K: Results of Operations and Financial Condition

MIAMI, July 27, 2026 – OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlight...

01 Jul 2026 SCHEDULE 13D/A
22 Jun 2026 Form 4: Lachman Prem A, Director

Granted 30,000 Stock Option (Right to Buy)

22 Jun 2026 Form 4: Medel Roger Md, Director

Granted 30,000 Stock Option (Right to Buy)

22 Jun 2026 Form 4: Paganelli John A, Director

Granted 30,000 Stock Option (Right to Buy)

22 Jun 2026 Form 4: Pfenniger Richard C Jr, Director

Granted 60,000 Stock Option (Right to Buy)

22 Jun 2026 Form 4: Uppaluri Subbarao V, Director

Granted 80,000 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support